These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 19475776)

  • 1. Safety and efficacy of rosiglitazone in the elderly diabetic patient.
    Viljoen A; Sinclair A
    Vasc Health Risk Manag; 2009; 5(1):389-95. PubMed ID: 19475776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety of rosiglitazone in the treatment of type 2 diabetes.
    Singh S; Loke YK
    Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
    Starner CI; Schafer JA; Heaton AH; Gleason PP
    J Manag Care Pharm; 2008; 14(6):523-31. PubMed ID: 18693776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2 diabetes, thiazolidinediones, and cardiovascular risk.
    Taylor C; Hobbs FD
    Br J Gen Pract; 2009 Jul; 59(564):520-4. PubMed ID: 19567003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The "glitazones": rosiglitazone and pioglitazone.
    Papoushek C
    J Obstet Gynaecol Can; 2003 Oct; 25(10):853-7. PubMed ID: 14532954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
    Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
    Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.
    Loke YK; Kwok CS; Singh S
    BMJ; 2011 Mar; 342():d1309. PubMed ID: 21415101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
    Breunig IM; Shaya FT; McPherson ML; Snitker S
    J Manag Care Spec Pharm; 2014 Sep; 20(9):895-903. PubMed ID: 25166288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.
    Hsiao FY; Huang WF; Wen YW; Chen PF; Kuo KN; Tsai YW
    Drug Saf; 2009; 32(8):675-90. PubMed ID: 19591532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.
    Derosa G
    Drugs; 2010 Oct; 70(15):1945-61. PubMed ID: 20883052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
    Tzoulaki I; Molokhia M; Curcin V; Little MP; Millett CJ; Ng A; Hughes RI; Khunti K; Wilkins MR; Majeed A; Elliott P
    BMJ; 2009 Dec; 339():b4731. PubMed ID: 19959591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
    Cobitz A; Zambanini A; Sowell M; Heise M; Louridas B; McMorn S; Semigran M; Koch G
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):769-81. PubMed ID: 18613278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular risk and TZD: safe therapy for the elderly?
    Burt R; Townsend S; Armor B
    Consult Pharm; 2009 May; 24(5):392-4. PubMed ID: 19555148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.
    Loke YK; Singh S; Furberg CD
    CMAJ; 2009 Jan; 180(1):32-9. PubMed ID: 19073651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
    Graham DJ; Ouellet-Hellstrom R; MaCurdy TE; Ali F; Sholley C; Worrall C; Kelman JA
    JAMA; 2010 Jul; 304(4):411-8. PubMed ID: 20584880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study.
    Douglas IJ; Evans SJ; Pocock S; Smeeth L
    PLoS Med; 2009 Sep; 6(9):e1000154. PubMed ID: 19787025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value equation for rosiglitazone and pioglitazone in older persons.
    Zarowitz BJ
    Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
    [No Abstract]   [Full Text] [Related]  

  • 19. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
    Home PD; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Jones NP; Komajda M; McMurray JJ;
    N Engl J Med; 2007 Jul; 357(1):28-38. PubMed ID: 17551159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
    De Flines J; Scheen AJ
    Rev Med Suisse; 2007 Aug; 3(122):1876, 1878-83. PubMed ID: 17896661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.